Genetic technologies limited
GENE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
GENE 近期報酬表現
3.78%
Genetic technologies limited
-2.56%
同產業平均
-1.46%
S&P500
與 GENE 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
BGXX | Bright green corp | - | 2 分 | 4 分 | - | 1 分 | |
PSNL | Personalis inc | 2 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
DNTH | Dianthus therapeutics inc | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
THAR | Tharimmune inc | - | 3 分 | 3 分 | 1 分 | 1 分 | |
TRAW | Traws pharma inc | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 |
- BGXX Bright green corp價值 -趨勢 2 分波段 4 分籌碼 -股利 1 分查看更多
GENE 公司資訊
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor